USPTO serial 79164322
3RND
Reviewed by CopyMark Law Group
Reg. 4943582Status 404
- Filing date
- Status date
- Registration date
- Apr 26, 2016
- Examiner
- CLARK, ROBERT C
- Law office
- —
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with 3RND?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey A. Smith
Jeffrey A. Smith Millen White Zelano and Branigan, PC2200 Clarendon BoulevardSuite 1400Arlington, VA 22201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | [ Database management software; software for application and database integration; software for creating searchable databases; computer application software for mobile phones, cellular phones, handheld computers, smart telephones, PC tablets, personal digital assistants, mobile computers, computers, namely, software used for analysis, storage, data retrieval and visualization of compounds and the cellular effect of compounds in drug discovery; bioinformatics software used to assess the cellular effect of compounds in the drug discovery and development process; computer graphics software; software for accessing information directories that may be downloaded from a global computer network; software for data storage automation; data search software, namely, software for creating searchable database of data; digital image processing software; software for data and document capture, transmission, storage and indexing; scanning software ] | SECTION 71 - CANCELLED | — |
| 042 | [ Scientific research and development; ] scientific and technological services, namely, novel multi-parametric phenotypic screening in the nature of analytical testing [ services and protein isolation ] for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical research, drug discovery and characterization of compound effect [, and scientific research and development relating thereto ] ; Scientific and technological services for scientific analysis, testing and research in the fields of pharmaceutical research, drug discovery and characterization of compound effect [, and protein separation, isolation and characterization ] ; [ scientific research services; ] scientific testing and analysis in the fields of pharmaceutical research, drug discovery and characterization of compound effect [, and protein separation, isolation and characterization ] ; computer-assisted scientific research, testing and analysis services in the fields of pharmaceutical research, drug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxin, where a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; [ laboratory research and analysis services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; pharmaceutical research and development; ] Scientific research and scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; scientific laboratory services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research; provision of scientific information on technological research in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; ] provision of scientific information about industrial analysis and research services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; [ provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and ] scientific consultancy services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research ] | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 10, 2025 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Oct 10, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Apr 26, 2025 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Mar 17, 2024 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Feb 3, 2024 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Feb 2, 2024 | INPC | INVALIDATION PROCESSED | — |
| Jan 25, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 25, 2023 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| May 25, 2023 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| May 16, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 25, 2022 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Apr 26, 2021 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 12, 2016 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 27, 2016 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 27, 2016 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 26, 2016 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 26, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 9, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 9, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2016 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 20, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 20, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 20, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 4, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 17, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 17, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 29, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 29, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 11, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 22, 2015 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 22, 2015 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 19, 2015 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 18, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 18, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2015 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 2, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 30, 2015 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |